CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
MILs +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00566098
NCT00566098Phase 2Completed
CompareCT.gov

Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes in the Autologous Transplant Setting in Multiple Myeloma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Dec 3, 2007·Updated May 26, 2023

In Brief

A Phase 2 clinical trial evaluating MILs, Melphalan, and 1 other intervention for Multiple Myeloma and Plasma Cell Neoplasm. Completed, enrolled 26 participants across 1 site.

Detailed Summary

RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer cells when they are put back in the body. This may be an effective treatment for patients undergoing a stem cell transplant for multiple myeloma. PURPOSE: This phase I/II trial is studying the side effects of activated white blood cells and to see how well they work in treating patients who are undergoing a stem cell transplant for newly diagnosed stage II or stage III multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma and Plasma Cell Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 3, 2007
Enrollment StartNov 1, 2007
Primary CompletionJun 1, 2014
Study CompletionOct 1, 2018
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 18.6 years ago

Interventions

MILsbiological

Melphalandrug

PCV13biological